We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
- Authors
Nauck, M A; Ellis, G C; Fleck, P R; Wilson, C A; Mekki, Q; Alogliptin Study 008 Group
- Abstract
To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase-4 inhibitor, for 26 weeks at once-daily doses of 12.5 and 25 mg in combination with metformin in patients whose HbA(1c) levels were inadequately controlled on metformin alone.
- Publication
International journal of clinical practice, 2009, Vol 63, Issue 1, p46
- ISSN
1742-1241
- Publication type
Journal Article
- DOI
10.1111/j.1742-1241.2008.01933.x